Streetbeat News

Products Services

ALCE

Alternus Clean Energy Inc (NASDAQ:ALCE) shares surged after announcing a joint venture with Acadia Energy to co-develop 200 MW of Sustainability Hub microgrid projects in New York State. The partnership aims to leverage both companies' strengths in renewable energy, with Alternus holding a 51% majority stake. The projects are expected to start operations within two years, contributing to local economic growth and sustainability.

Portfolio Pulse from Shivani Kumaresan

April 04, 2024 | 4:20 pm

NVS

Novartis shares are trading higher following the company's announcement to file for Pluvicto pre-taxane label expansion in H2 2024, based on positive Phase III PSMAfore study results.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 4:18 pm

BNTX

CVAC

GSK

CureVac N.V. (CVAC) and GSK Plc (GSK) released interim data from their seasonal influenza vaccine study, showing promising results across all age groups and dose levels. The vaccine, designed for broad antigen coverage, demonstrated strong antibody titers and an acceptable safety profile. The study is part of a collaboration between CureVac and GSK, focusing on a multivalent vaccine candidate using CureVac's second-generation mRNA technology. Additionally, CureVac is involved in ongoing patent litigation with BioNTech SE (BNTX) over intellectual property rights.

Portfolio Pulse from Vandana Singh

April 04, 2024 | 4:18 pm

NVS

Novartis announced plans to file for a label expansion of Pluvicto in H2 2024, based on data from the Phase III PSMAfore study. This move aims to broaden the use of Pluvicto before taxane treatment in patients, potentially enhancing its market and therapeutic reach.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 4:12 pm

VUZI

Vuzix shares are trading higher following the announcement of receiving new additional orders from two aerospace and defense firms for the development and delivery of waveguide-based display solutions in 2024.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 4:09 pm

MGNX

Analyst ratings for Macrogenics (NASDAQ:MGNX) have shown a diverse range of opinions, with recent updates indicating a positive shift. Over the past quarter, 10 analysts have provided ratings, with a notable increase in the 12-month price target to $21.8, up 48.3% from the previous $14.70. This adjustment reflects optimism based on the company's potential, despite challenges in revenue growth and financial metrics. Macrogenics, a biotech firm focusing on cancer therapeutics, has seen its market position and financial performance analyzed, revealing areas of concern such as a significant revenue decline and below-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:01 pm

VVOS

Vivos Therapeutics' shares surged following the announcement of a notice of allowance for its U.S. patent application for a device aimed at treating sleep disordered breathing, sleep apnea, and snoring.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 4:01 pm

TSLA

Tesla shares are trading higher, potentially due to Ford's delay in its all-electric SUV production. Additionally, Tesla is considering importing cars made at Giga-Berlin to India.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 4:00 pm

ACHL

ALUR

CADL

CAG

EFTR

KWE

TCBP

Nasdaq rose 1% with ConAgra Brands reporting better-than-expected Q3 earnings, leading to a positive market sentiment. Real estate and healthcare sectors saw gains, while TC Biopharm, Allurion Technologies, and Candel Therapeutics experienced significant stock increases. Conversely, eFFECTOR Therapeutics, Achilles Therapeutics, and KWESST Micro Systems saw notable declines. Oil prices slightly dropped, while gold and silver prices increased.

Portfolio Pulse from Avi Kapoor

April 04, 2024 | 3:58 pm

NFLX

Netflix (NASDAQ:NFLX) has seen a surge in options activity, with a bearish sentiment prevailing among investors. Analysis of 36 trades reveals 30% bullish and 69% bearish expectations. The price target window is between $300 and $800. Recent options trading patterns indicate a focus on high-value trades within this price range. Netflix's business model, focusing on streaming services without live programming, has garnered nearly 250 million subscribers globally. The stock is currently up 0.3% at $632.0, with potential overbought signals. Analyst ratings suggest a consensus target price of $685.0, with varying recommendations from Outperform to Neutral.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 3:46 pm